Short Interest in Vor Biopharma Inc. (NASDAQ:VOR) Decreases By 17.3%

02 May 2026, 06:39 by Jessica Moore · The Cerbat Gem

Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 4,706,707 shares, a decline of 17.3% from the March 31st total of 5,687,983 shares. Approximately 9.7% of the company’s shares are sold short. Based on an average daily volume of 1,347,900 shares, the short-interest ratio is currently 3.5 days.

Analyst Ratings Changes

Several analysts have weighed in on VOR shares. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday. HC Wainwright lowered their price objective on shares of Vor Biopharma from $32.00 to $31.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Wedbush upped their price objective on shares of Vor Biopharma to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Wells Fargo & Company assumed coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective for the company. Finally, Citigroup assumed coverage on shares of Vor Biopharma in a research note on Friday, January 9th. They set a “buy” rating and a $50.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Vor Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $50.56.

Check Out Our Latest Research Report on VOR

Vor Biopharma Trading Down 3.3%

Shares of NASDAQ:VOR opened at $13.85 on Friday. The company has a market cap of $750.48 million, a price-to-earnings ratio of -0.04 and a beta of 1.92. The company has a 50-day moving average price of $14.98 and a 200-day moving average price of $15.14. Vor Biopharma has a 12 month low of $2.62 and a 12 month high of $65.80.

Insiders Place Their Bets

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 165,150 shares of the business’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total value of $2,604,415.50. Following the completion of the sale, the director directly owned 2,402,095 shares of the company’s stock, valued at $37,881,038.15. The trade was a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 3,002,903 shares of company stock valued at $49,412,176 over the last ninety days. Insiders own 0.45% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of VOR. Goldman Sachs Group Inc. increased its position in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares during the period. Jane Street Group LLC purchased a new position in shares of Vor Biopharma during the first quarter valued at about $140,000. XTX Topco Ltd purchased a new position in shares of Vor Biopharma during the second quarter valued at about $66,000. Ariose Capital Management Ltd purchased a new position in shares of Vor Biopharma during the third quarter valued at about $5,368,000. Finally, BNP Paribas Financial Markets increased its position in shares of Vor Biopharma by 497.3% during the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after buying an additional 5,058 shares during the period. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

(Get Free Report)

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.